Merck & Co. (MRK) 8-K Merck Announces First-Quarter 2019 Financial Results

Exhibit 99.2

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF INCOME - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

	2019			2018															% Change
	1Q			1Q			2Q			3Q			4Q			Full Year			1Q
Sales	$	10,816		$	10,037		$	10,465		$	10,794		$	10,998		$	42,294		8	%
Costs, Expenses and Other
Cost of sales	3,052			3,184			3,417			3,619			3,289			13,509			-4	%
Selling, general and administrative	2,425			2,508			2,508			2,443			2,643			10,102			-3	%
Research and development	1,931			3,196			2,274			2,068			2,214			9,752			-40	%
Restructuring costs	153			95			228			171			138			632			61	%
Other (income) expense, net	188			(291		)	(48		)	(172		)	110			(402		)	*
Income Before Taxes	3,067			1,345			2,086			2,665			2,604			8,701			*
Taxes on Income	205			604			370			707			826			2,508
Net Income	2,862			741			1,716			1,958			1,778			6,193			*
Less: Net (Loss) Income Attributable to Noncontrolling Interests	(53		)	5			9			8			(49		)	(27		)
Net Income Attributable to Merck & Co., Inc.	$	2,915		$	736		$	1,707		$	1,950		$	1,827		$	6,220		*
Earnings per Common Share Assuming Dilution	$	1.12		$	0.27		$	0.63		$	0.73		$	0.69		$	2.32		*
Average Shares Outstanding Assuming Dilution	2,603			2,710			2,696			2,678			2,634			2,679
Tax Rate	6.7		%	44.9		%	17.8		%	26.5		%	31.7		%	28.8		%

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

MERCK & CO., INC.

GAAP TO NON-GAAP RECONCILIATION

FIRST QUARTER 2018

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2b

	GAAP			Acquisition and Divestiture-Related Costs (1)		Restructuring Costs (2)		Certain Other Items (3)		Adjustment Subtotal		Non-GAAP
Cost of sales	$	3,184		734		6				740		$	2,444
Selling, general and administrative	2,508			8		1				9		2,499
Research and development	3,196			1		2		1,400		1,403		1,793
Restructuring costs	95					95				95		—
Other (income) expense, net	(291		)	(10	)			(22	)	(32	)	(259		)
Income Before Taxes	1,345			(733	)	(104	)	(1,378	)	(2,215	)	3,560
Income Tax Provision (Benefit)	604			(91	)(4)	(21	)(4)	5	(4)	(107	)	711
Net Income	741			(642	)	(83	)	(1,383	)	(2,108	)	2,849
Net Income Attributable to Merck & Co., Inc.	736			(642	)	(83	)	(1,383	)	(2,108	)	2,844
Earnings per Common Share Assuming Dilution	$	0.27		(0.24	)	(0.03	)	(0.51	)	(0.78	)	$	1.05
Tax Rate	44.9		%									20.0		%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management’s annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions.  Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures.  Amounts included in research and development expenses reflect increases in the estimated fair value measurement of liabilities for contingent consideration.  Amounts included in other (income) expense, net reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of Sanofi-Pasteur MSD joint venture.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company’s formal restructuring programs.

(3) Amount included in research and development expenses represents an aggregate charge related to the formation of a collaboration with Eisai Co., Ltd.

(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FIRST QUARTER 2019

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3a

	Global					U.S.						International
	1Q 2019		1Q 2018		% Change	1Q 2019			1Q 2018		% Change	1Q 2019		1Q 2018			% Change
TOTAL SALES (1)	$	10,816	$	10,037	8	$	4,515		$	4,133	9	$	6,301	$	5,904		7
PHARMACEUTICAL	9,663		8,919		8	4,175			3,716		12	5,488		5,202			5
Oncology
Keytruda	2,269		1,464		55	1,284			838		53	985		626			57
Emend	117		125		-7	63			79		-20	53		46			15
Alliance Revenue - Lynparza	79		33		141	50			24		110	29		9			*
Alliance Revenue - Lenvima	74					50						24
Vaccines (2)
Gardasil / Gardasil 9	838		660		27	362			380		-5	476		280			70
ProQuad / M-M-R II / Varivax	496		392		27	343			312		10	153		80			91
RotaTeq	211		193		10	154			151		2	57		42			35
Pneumovax 23	185		179		3	125			112		12	59		66			-10
Vaqta	47		37		28	29			18		58	18		18			-1
Hospital Acute Care
Bridion	255		204		25	119			80		48	136		124			10
Noxafil	190		176		8	91			81		12	99		94			5
Cubicin	88		98		-10	42			47		-10	46		51			-10
Invanz	72		151		-53	14			91		-85	58		60			-4
Cancidas	61		91		-33	1			3		-66	60		88			-31
Primaxin	59		72		-19				5		-95	59		67			-13
Immunology
Simponi	208		231		-10							208		231			-10
Remicade	123		167		-26							123		167			-26
Neuroscience
Belsomra	67		54		24	24			23		1	44		31			41
Virology
Isentress / Isentress HD	255		281		-9	108			128		-16	147		152			-3
Zepatier	114		131		-13	33					*	81		131			-38
Cardiovascular
Zetia	140		305		-54				17		-98	140		287			-51
Vytorin	97		167		-42	3			8		-64	94		158			-40
Atozet	94		73		29							94		73			29
Adempas	90		68		33							90		68			33
Diabetes (3)
Januvia	824		880		-6	384			465		-17	440		416			6
Janumet	530		544		-2	167			192		-13	364		352			3
Women’s Health
NuvaRing	219		216		1	185			171		9	34		46			-26
Implanon / Nexplanon	199		174		14	149			128		16	50		46			8
Diversified Brands
Singulair	191		175		9	5			6		-4	186		170			10
Cozaar / Hyzaar	103		120		-14	4			7		-41	99		113			-12
Nasonex	96		122		-22	(1		)	1		-152	97		121			-20
Arcoxia	75		83		-10							75		83			-10
Follistim AQ	57		67		-15	29			29		1	28		39			-28
Other Pharmaceutical (4)	1,140		1,186		-4	358			320		12	782		867			-10
ANIMAL HEALTH	1,025		1,065		-4	294			307		-4	731		758			-4
Livestock	611		652		-6	117			124		-6	494		529			-7
Companion Animals	414		413			177			183		-3	237		229			3
Other Revenues (5)	128		53		139	46			110		-58	82		(56		)	*

* 200% or greater

(1)     Only select products are shown.

(2)     Total Vaccines sales were $1,887 million and $1,561 million on a global basis for first quarter 2019 and 2018, respectively.

(3)     Total Diabetes sales were $1,402 million and $1,433 million on a global basis for first quarter 2019 and 2018, respectively.

(4)     Includes Pharmaceutical products not individually shown above.

(5)     Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

MERCK & CO., INC.

PHARMACEUTICAL GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3b

	2019			2018															% Change
	1Q			1Q			2Q			3Q			4Q			Full Year			1Q
TOTAL PHARMACEUTICAL	$	9,663		$	8,919		$	9,282		$	9,658		$	9,830		$	37,689		8
United States	4,175			3,716			3,841			4,649			4,402			16,608			12
% Pharmaceutical Sales	43.2		%	41.7		%	41.4		%	48.1		%	44.8		%	44.1		%
Europe (1)	2,335			2,402			2,322			2,114			2,237			9,076			-3
% Pharmaceutical Sales	24.2		%	26.9		%	25.0		%	21.9		%	22.8		%	24.1		%
Japan	779			718			834			740			835			3,127			8
% Pharmaceutical Sales	8.1		%	8.1		%	9.0		%	7.7		%	8.5		%	8.3		%
Asia Pacific	1,367			1,112			1,224			1,054			1,199			4,589			23
% Pharmaceutical Sales	14.1		%	12.5		%	13.2		%	10.9		%	12.2		%	12.2		%
China	725			459			530			488			601			2,077			58
Latin America	427			398			459			493			530			1,880			7
% Pharmaceutical Sales	4.4		%	4.5		%	4.9		%	5.1		%	5.4		%	5.0		%
Eastern Europe/Middle East Africa	343			335			356			347			349			1,388			2
% Pharmaceutical Sales	3.6		%	3.8		%	3.8		%	3.6		%	3.6		%	3.7		%
Canada	177			196			192			177			211			776			-10
% Pharmaceutical Sales	1.8		%	2.2		%	2.1		%	1.8		%	2.1		%	2.1		%
Other	60			42			54			84			67			245			43
% Pharmaceutical Sales	0.6		%	0.5		%	0.6		%	0.9		%	0.7		%	0.7		%

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.

OTHER (INCOME) EXPENSE, NET - GAAP

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 4

OTHER (INCOME) EXPENSE, NET

	1Q19			1Q18
Interest income	$	(89	)	$	(85	)
Interest expense	209			185
Exchange losses	101			7
Loss (income) from investments in equity securities, net (1)	25			(25		)
Net periodic defined benefit plan (credit) cost other than service cost	(141		)	(135		)
Other, net	83			(238		)
Total	$	188		$	(291	)

(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.